Functional genomics is revolutionizing cancer research by elucidating the roles of genes and their interactions in tumorigenesis. In 2025, the integration of advanced technologies and methodologies is propelling the field towards more precise and personalized… What’s Next for Functional Cancer Genome Tools?
Cancer remains a leading cause of mortality worldwide, necessitating the continuous exploration of novel biomarkers and therapeutic targets. Nuclear receptors (NRs), a family of 48 ligand-dependent transcription factors, have emerged as pivotal players in cancer biology. … Why Nuclear Receptors Offer Powerful Cancer Biomarkers and Targets
Cancer remains one of the most formidable challenges in modern medicine, with treatment resistance and relapse posing significant hurdles. Recent research highlights the potential of combining Bromodomain and Extra-Terminal (BET) protein inhibition with Poly(ADP-ribose) polymerase (PARP) inhibitors to enhance… How BET Repression and PARP Inhibition Can Combat Cancer—Data from FCG